The Arctic Front Advance catheter-based cardiac cryoballoon for paroxysmal atrial fibrillation gained both PMA supplement approval and a CE mark, Medtronic PLC announced Aug. 24. The firm expects to make the second-generation product available throughout the U.S. and Europe in the early fall. Compared to the original Arctic Front cryoablation system, which was launched in the U.S. in 2010, the Arctic Front Advance improves physicians’ ability to treat patients with complicated anatomies by employing new EvenCool technology to optimize the delivery of coolant inside the balloon. It is intended to provide a more uniform cold surface to reduce the effort needed to isolate the pulmonary veins, the company explains. The cryoballoon technology is associated with faster procedure times versus point-by-point radiofrequency ablation. (See Also see "News In Brief" - Medtech Insight, 20 December, 2010..)
The Arctic Front Advance cryoablation device is designed to improve physicians’ ability to treat patients with complicated anatomies by optimizing the delivery of coolant inside the balloon.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?